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INTRODUCTION
Breast cancer is the most frequency malignancy in
women in developed countries. It is estimated that
approximately 7% of women with breast cancer
are diagnosed before the age of 40 years, and this
disease accounts for more than 40% of all cancer
in women in this age group.1 Breast cancer is likely
to have a negative impact on reproductive function
from the toxic effect of chemotherapy on ovarian
follicles.2 Young women with more primordial
oocytes showed a significant reduction of their
ovarian reserve following chemotherapy.3 Chemo-
therapy causes acute loss of growing follicles
resulting in premature ovarian failure, shortened
reproductive life span and hormone deficiency.4,5
Cyclophosphamide, also known as cytophos-
phane, is a nitrogen mustard alkylating agent from
the oxazophorine group. Cyclophosphamide is
used to treat various types of cancer and some
autoimmune disorders by slowing-down or
stopping cell growth.6 Cyclophosphamide, alone or
in combination with other chemotherapy agents, is
used for the treatment of lymphomas, some forms
of leukemia, and some types of solid tumours
including breast cancer. Gonadal failure is a major
complication of cyclophosphamide administration,
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Abstrak
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especially in females.7 Cyclophosphamide affects
primordial follicle density rapidly after injection
of this agent. Human coocytes are damaged
drastically followed by ganulosa cells.8
The granulosa cells of primary follicles produced
Anti-Müllerian Hormone (AMH).9,15 AMH is a
glycoprotein hormone belonging to transforming
growth factor b family. It’s levels reflect the
continuous non-cyclical growth of small follicles.10
Women with abnormal level of this hormone
impaired the ovarian reserved followed by
fertility.11 This study aimed to evaluate the levels
of AMH in breast cancer patients treated with
cyclosphosphamide chemotherapy.
METHODS
This cohort prospective study was conducted in Dr.
Wahidin Sudirohusodo Hospital in the Department
of Obstetrics and Gynecology in collaboration with
Department of Surgery, Faculty of Medicine,
Universitas Hasanuddin between September 2015
and June 2016. The study protocol was approved
by the Health Research Ethics Committee of
Faculty of Medicine, Universitas Hasanuddin.
Eligible patients were women with breast cancer,
aged 20 to 48 years, who were to receive three
series of cyclophosphamide treatment but who had
not received chemotherapy previously. Prior
chemotherapy, radiation therapy, oophorectomy,
and patients who did not complete the first series
of chemotherapy cycles until the third series were
ineligible. Serum levels of AMH in each series of
chemotherapy were measured at Prodia Clinical
Laboratory Jakarta using AMH Enzyme Linked
Immuno Sorbent Assay (ELISA) kits. Statistical
analysis was performed using SPSS. A two-sided p
value <.05 was considered statistically significant.
RESULTS
The study included 40 women with breast cancer
who completed the three series of cyclophos-
phamide chemotherapy. Table 1 summarizes the
characteristics of the patients. Seventy percent of
the patients were aged 36-47 years, 52.5% had
senior high school education, majority of patients
had married (87.5%) and multiparity (51.4%).
Table 1. Subject characteristics
Variables n %
Age (years)
 29 - 35 12 30.0
 36 - 47 28 70.0
Education
 SMP 12 30.0
 SMA 21 52.5
 College 7 17.5
Marital status
 Married 35 87.5
 Unmarried 5 12.5
Parity
 0 3 8.6
 1 - 2 14 40.0
 > 2 18 51.4
Decreased serum AMH levels were seen after
each series of cyclophosphamide chemotherapy;
first series from 2.092.04 g/ml to 0.651.06
g/ml, second series from 4.033.47 g/ml to
1.301.40 and third series from 1.531.34 to
0.500.65 g/ml. There was an overall significant
decrease in serum AMH levels (p<0.05) for the
three series of chemotherapy (Table 2).
DISCUSSION
In reproductive-aged women treated with chemo-
therapy and radiotherapy for malignancy, serum
AMH levels could be used to predict the ovarian
Table 2. AMH Levels in the Series of Cyclosphosphamide Chemotherapy of Breast Cancer
Series of chemotherapy AMH levels (meanSD g/ml) p
Prechemotherapy Postchemotherapy
First 2.092.04 0.651.06 0.000
Second 4.033.47 1.301.40 0.003
Third 1.531.34 0.500.65 0.010
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reserve.12 Chemotherapy has a negative effect on
the ovarium that cause the loss of primordial
follicles, thus the levels of serum AMH as a marker
for early prediction of the ovarian reserve.13
We found that there was a significant decrease
in serum AMH levels in breast cancer patient
treated with cyclophosphamide in the present
study. AMH and inhibin B levels immediately
decreased after chemotherapy.14 AMH hormone is
produced predominantly in primary, preantral, and
small antral follicles.15 The growing follicles
appeared to be the target of chemotherapy
agents.14 Anders et al. conducted a study in AMH,
E2, FSH, inhibin B, and AFC for markers of ovarian
reserve in patients who received adjuvant
treatment. They observed significantly decreased
or undetectable serum AMH levels after chemo-
therapy similar to other previous studies.16
This study also found that AMH levels decreased
after the first series and along with the next series
of chemotherapy. Our results similar to previous
study on breast cancer treated with cyclophos-
phamide that serum AMH levels decreased from
first series (2.71.0 ng/ml) to second series
(0.40.4 ng/ml).14 Another study also assayed
AMH and other hormonal markers before, during
and after chemotherapy administration and
reported the decreased serum AMH levels after
chemotherapy indicating direct chemotherapy
induced damage to the granulose cells and hence
growing follicles and ultimately the follicle pool
resulting in decreased ovarian reserved.17
AMH levels differ among breast cancer patients
that received chemotherapy due to dose
administration. Study found that difference dose
correlated with AMH levels 0.52 ng/ml, 1.99 ng/ml
and 3.09 ng/ml in high dose, low dose and not
exposed to chemotherapy, respectively. Increased
dose of chemotherapy has greater reduction in
AMH levels (Gracia et al., 2012).18
AMH levels variations before, during and after
chemotherapy provide information about the
degree of follicle loss for each patient according to
different chemotherapy regimens. Different
patterns of AMH levels during the ovarian recovery
phase make it possible to discriminate between
high and low gonadotoxic chemotherapy protocols.
In addition, pretreatment AMH levels are shown to
predict the long-term ovarian function after the
end of treatment. These provide a better under-
standing on the ovarian toxicity mechanisms of
chemotherapy and to predict the degree of the
ovarian follicle loss. Therefore, it can be useful for
fertility preservation strategies, fertility counseling
and future family planning.19
CONCLUSION
AMH levels decreased significant after cyclophos-
phamide chemotherapy. This is indicated that
cyclosphosphamide decreased ovarian reserve.
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